↓ Skip to main content

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II…

Overview of attention for article published in BMC Medicine, April 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)

Mentioned by

news
46 news outlets
twitter
5 tweeters

Readers on

mendeley
14 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Published in
BMC Medicine, April 2022
DOI 10.1186/s12916-022-02305-4
Pubmed ID
Authors

Lugui Qiu, Zhongjun Xia, Chengcheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Fei Li, Zhuogang Liu, Xiequn Chen, Jing Liu, Aihua Wang, Yang Yu, Wenxi Xiang, Kevin Lynch, Zhinuan Yu, Weijun Fu

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 4 29%
Researcher 4 29%
Lecturer 1 7%
Student > Master 1 7%
Unknown 4 29%
Readers by discipline Count As %
Medicine and Dentistry 5 36%
Unspecified 2 14%
Biochemistry, Genetics and Molecular Biology 2 14%
Computer Science 1 7%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Other 0 0%
Unknown 3 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 350. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2022.
All research outputs
#69,222
of 21,799,263 outputs
Outputs from BMC Medicine
#68
of 3,190 outputs
Outputs of similar age
#2,130
of 342,088 outputs
Outputs of similar age from BMC Medicine
#1
of 1 outputs
Altmetric has tracked 21,799,263 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,190 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 42.6. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,088 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them